About: PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Sector: Healthcare
Industry: Biotechnology
Latest price: $64.46 (+2.29%)
PTCT NASDAQ PTC Therapeutics Inc
PTC Therapeutics Inc share price
Atividade de preço de PTCT
Último preço
$ 64,460
Variação (24h)
1,44 USD (2,29%)
Volume
1.52M
Volume (média 4 sem.)
-
Abertura
$ 63,51
Variação do dia
$ 63,51 - $ 65,00
Fechamento anterior
$ 63,02
Último negócio
29 Oct, 8:28 pm GMT+0
Atrasado
29 Oct, 8:28 pm GMT+0
PTCT price performance
Atrasado
29 Oct, 8:28 pm GMT+0
quote.marketSignals